dapagliflozin
Selected indexed studies
- Dapagliflozin: A Review in Type 2 Diabetes. (Drugs, 2019) [PMID:31236801]
- Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. (Clin Pharmacokinet, 2014) [PMID:24105299]
- Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. (J Am Soc Nephrol, 2021) [PMID:34272327]
_Worker-drafted node — pending editorial review._
Connections
dapagliflozin is a side effect of
Sources
- Dapagliflozin: A Review in Type 2 Diabetes. (2019) pubmed
- Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. (2014) pubmed
- Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. (2021) pubmed
- Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2. (2023) pubmed
- Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure. (2024) pubmed
- Early Clinical Experience with Dapagliflozin in Children with Heart Failure. (2023) pubmed
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. (2021) pubmed
- Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial. (2022) pubmed
- Dapagliflozin in acute heart failure management: a systematic review and meta-analysis of safety and effectiveness. (2024) pubmed
- Dapagliflozin: A Review in Type 1 Diabetes. (2019) pubmed